PolyPid Ltd. (NASDAQ:PYPD – Free Report) – Equities research analysts at HC Wainwright increased their FY2026 EPS estimates for PolyPid in a research report issued on Thursday, November 12th. HC Wainwright analyst B. Folkes now expects that the company will earn ($1.41) per share for the year, up from their prior estimate of ($1.67). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2026 earnings at ($0.46) EPS, FY2027 earnings at ($0.58) EPS and FY2028 earnings at ($0.21) EPS.
PolyPid (NASDAQ:PYPD – Get Free Report) last issued its quarterly earnings results on Wednesday, November 11th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of $0.91 by ($1.15). The company had revenue of $30.00 million for the quarter, compared to analyst estimates of $30.00 million.
A number of other equities research analysts also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of PolyPid in a research report on Friday, September 18th. Wall Street Zen lowered PolyPid from a “buy” rating to a “hold” rating in a research note on Saturday. Craig Hallum set a $12.00 price target on PolyPid in a report on Wednesday, July 22nd. Finally, Oppenheimer started coverage on PolyPid in a research report on Tuesday, October 27th. They issued an “outperform” rating and a $10.00 price objective for the company. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, PolyPid currently has an average rating of “Moderate Buy” and an average target price of $11.67.
Get Our Latest Analysis on PYPD
PolyPid Stock Performance
NASDAQ:PYPD opened at $6.15 on Monday. The company has a market cap of $117.34 million, a price-to-earnings ratio of -4.56 and a beta of 1.43. The stock’s fifty day moving average price is $5.38 and its two-hundred day moving average price is $4.81. PolyPid has a 52-week low of $3.50 and a 52-week high of $7.15.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in PYPD. HighTower Advisors LLC grew its stake in shares of PolyPid by 18.2% during the third quarter. HighTower Advisors LLC now owns 13,000 shares of the company’s stock worth $69,000 after purchasing an additional 2,000 shares during the period. B. Riley Wealth Advisors Inc. increased its holdings in PolyPid by 32.7% in the third quarter. B. Riley Wealth Advisors Inc. now owns 20,085 shares of the company’s stock valued at $106,000 after purchasing an additional 4,955 shares during the last quarter. AXQ Capital LP acquired a new position in PolyPid in the second quarter valued at about $87,000. Renaissance Technologies LLC acquired a new position in PolyPid in the first quarter valued at about $81,000. Finally, Connective Capital Management LLC acquired a new position in PolyPid in the second quarter valued at about $343,000. 26.47% of the stock is currently owned by institutional investors.
PolyPid Company Profile
PolyPid Ltd. is an Israeli clinical-stage biopharmaceutical company developing products designed to deliver medicines locally and over an extended period. Its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology is intended to control the release of drugs at the site where they are administered. The company’s lead product candidate, D-PLEX100, uses the antibiotic doxycycline and is designed to be applied during surgery to provide sustained local drug delivery for the prevention of surgical-site infections.
Recommended Stories
- Five stocks we like better than PolyPid
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
